Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13542691 | 0.85 | CYP1A2 (0.40) | CYP1A2ANPEPKCNMA1 | |
| SCHEMBL20362413 | 0.85 | CYP1A2 (0.40) | CYP1A2ANPEPKCNMA1 | |
| SCHEMBL13542693 | 0.84 | NAMPT (0.41) | NAMPTCYP1A2ANPEP | |
| SCHEMBL19296374 | 0.84 | CYP1A2 (0.39) | CYP1A2ANPEPKCNMA1 | |
| SCHEMBL23330459 | 0.83 | NR1H4 (0.38) | CYP1A2 | |
| SCHEMBL27387051 | 0.80 | GGPS1 (0.37) | CYP1A2 | |
| SCHEMBL22803403 | 0.79 | DGAT1 (0.40) | — | |
| SCHEMBL19296375 | 0.78 | CYP1A2 (0.41) | CYP1A2 | |
| SCHEMBL24307793 | 0.78 | HDAC1 (0.38) | CYP1A2 | |
| SCHEMBL23772122 | 0.78 | NR1H4 (0.35) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321253-A1 | BIFUNCTIONAL COMPOUNDS AND PHARMACEUTICAL USES THEREOF | KRAS, MDM2, NRAS | NAMPT 3765/4885CYP1A2 4519/4885ACHE 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.